All In Biotech

Drug Trial Radar · NCT07755956

Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis

A Phase Ia Clinical Trial to Compare Pharmacokinetics, Pharmacodynamics, Safety and Preliminary Efficacy of HHK001 Versus Enantone in Patients With Endometriosis

Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Oct 31, 2026

Primary completion

Mar 31, 2027

Study completion Mar 31, 2027

Sponsor

Sponsor type
Industry
First posted
Aug 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to find out how the study drug HHK001 compares to Enantone (an approved treatment for endometriosis) when given as a single 3.75 mg injection to participants with endometriosis. Both products contain the same active ingredient: leuprorelin acetate. We will check how the body absorbs and responds to each medicine, monitor possible side effects and treatment benefits. Researchers will compare HHK001 to Enantone to test the advantages of its updated formulation.

Conditions

  • Endometriosis

Interventions

  • HHK001Drug

    Participants will receive a single subcutaneous injection of 3.75 mg HHK001 (investigational leuprorelin acetate preparation).

  • EnantoneDrug

    Participants will receive a single subcutaneous injection of 3.75 mg Enantone (commercially-available leuprorelin acetate preparation).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Concentrations of leuprorelin acetateTime frame: Baseline through 70 days post-dose
  2. Concentrations of estradiolTime frame: Baseline through 70 days post-dose

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Suzhou Municipal Hospital (The Affiliated Suzhou Hospital of Nanjing Medical University)

    Suzhou, Jiangsu, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.